Glycoclusters and their pharmaceutical use as antibacterials
A molecule responding to formula (I) of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by Pseudomonas aeruginosa , more specifically as inhibitors of Pseudomonas aeruginosa 's virulence.
1. A molecule of formula (II):
Wherein
K is a carbohydrate selected from the group consisting of mannose, galactose, glucose, arabinose, xylose, ribose and lactose
Pho is a phosphorous group selected from the group consisting of:
Wherein X is selected from the group consisting of O or S, One or two oxygen atoms of the phosphate group being linked by a covalent link to a L1 linker arm,
L1 is a linker arm selected from the group consisting of:
a linear or branched C 1 -C 3 alkyl di radical, a linear, branched or cyclic C 4 -C 6 alkyl di radical, a linear, branched or cyclic C 7 -C 12 alkyl di radical possibly comprising one to three ether bridges —O—,
a poly(ethylene glycol) di radical comprising 2, 3, 4, 5 or 6 ethylene glycol units,
a polypropyleneglycol di radical comprising 2, 3, 4, 5 or 6 propylene glycol units,
T is a connecting group selected from:
a triazole di-radical
L2 is a linker arm selected from the group consisting of
n and m is an integer selected from 1, 2, 3, 4, or 5
Ar is selected from the group consisting of phenyl, naphtalenyl and 1,4-biphenyl
L3 is selected from the group consisting of O, S or —CH2
Gal is the radical β-D-galactopyranosyl:
z is an integer selected from 1, 2 3, 4, 5, 6, 7, 8, 9 or 10.
2. The molecule according to claim 1 , wherein K represents the mannose under the form D-mannopyranosyl.
3. The molecule according to claim 1 , wherein L1 represents a group Pro (1,3-n-propyl), EG2M (diethylene glycol methylene), EG3M (triethylene glycol methylene), EG4M (tetraethylene glycol methylene).
4. The molecule according to claim 1 , wherein Ar is a phenyl group.
5. The molecule according to claim 1 , wherein z is 3 or 4.
6. The molecule according to claim 1 , selected from the group consisting of:
Man(POProTzAcNPh-O-Gal) 4
Gal(POProTzAcNPh-O-Gal) 4
Glc(POProTzAcNPh-O-Gal) 4
Man(POEG 2 MTzAcNPh-O-Gal) 4
Man(POProTzAcNPh-O-Gal) 8
Man[POTHME(MTzAcNPh-O-Gal) 2 ] 4
Man(PSEG2MTzAcNPh-CH2-O-Gal) 4
Man(PSEG3MTzAcNPh-CH2-O-Gal) 4
Man(POEG2MTzAcNPh-CH2-O-Gal) 4
Man(POEG3MTzAcNPh-CH2-O-Gal) 4
Man(POEG2MTzAcNPh-CH2-SGal) 4
Man(POEG3MTzAcNPh-CH2-SGal) 4
Man(PSEG3MTzAcNPh-O-Gal) 4
Man(PSEG3MTzAcNPh-CH2-SGal) 4
Man(PSEG2MTzAcNPh-CH2-SGal) 4
Man(PSEG3MTzAcNPh-SGal) 4
Man(PSEG2MTzAcNPh-O-Gal) 4
Man(PSEG2MTzAcNPh-S-Gal) 4
Man(POEG2MTzAcNPh-S-Gal) 4
Man(POEG3MTzAcNPh-S-Gal) 4
Man(POEG3MTzproNCONapht-O-Gal) 4
Man(POEG3MTzproNCOBisph-O-Gal) 4
Man(PSEG3MTzproNCOBisph-O-Gal) 4
Man(PSEG2MTzproNCOBisph-O-Gal) 4
Man(POEG2MTz AcNPh-O-Gal) 4
Man(PSEG3MTzproNCONapht-O-Gal) 4
Man(POEG3MTz AcNPh-O-Gal) 4
Man(PSEG2MTzproNCONapht-O-Gal) 4
Man(POEG2MTzproNCOBisphe-O-Gal) 4
Man(POEG2MTzproNCONapht-O-Gal) 4 ,
wherein Man represents mannose, Gal represents galactose, Glc represents glucose, Ph represents phenyl, Napht represents naphthyl, Bisph represents biphenyl, PO represents phosphodiester, and PS represents phosphorothioate.
7. A pharmaceutical composition comprising at least one compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or excipient.
8. The pharmaceutical composition according to claim 7 formulated to be inhaled or instilled in the respiratory tract.
9. The pharmaceutical composition according to claim 7 , wherein the molecule of formula (II) comprises an antibacterial agent, and wherein the composition further comprises at least one or more other antibacterial agent(s) or one or more antiviral agent(s) or one or more drug(s) reinforcing the host innate immunity.
10. A method of treating a patient with an infection due to microbial pathogens comprising administering an effective amount of the pharmaceutical composition according to claim 7 .
11. A method of treating a patient with an infection from Pseudomonas aeruginosa comprising administering an effective amount of the pharmaceutical composition according to claim 10 .
12. A method of capturing Pseudomonas aeruginosa in a substance containing Pseudomonas aeruginosa , the method comprising adding to the substance an effective amount of a composition comprising at least one compound according to claim 1 .
13. The molecule according to claim 2 , wherein L1 represents a group Pro (1,3-n-propyl), EG2M (diethylene glycol methylene), EG3M (triethylene glycol methylene), EG4M (tetraethylene glycol methylene).
14. The molecule according to claim 2 , wherein Ar is a phenyl group.
15. The molecule according to claim 2 , wherein z is 3 or 4.
16. The molecule according to claim 2 , selected from the group consisting of:
Man(POProTzAcNPh-O-Gal) 4
Gal(POProTzAcNPh-O-Gal) 4
Glc(POProTzAcNPh-O-Gal) 4
Man(POEG 2 MTzAcNPh-O-Gal) 4
Man(POProTzAcNPh-O-Gal) 8
Man[POTHME(MTzAcNPh-O-Gal) 2 ] 4
Man(PSEG2MTzAcNPh-CH2-O-Gal) 4
Man(PSEG3MTzAcNPh-CH2-O-Gal) 4
Man(POEG2MTzAcNPh-CH2-O-Gal) 4
Man(POEG3MTzAcNPh-CH2-O-Gal) 4
Man(POEG2MTzAcNPh-CH2-S-Gal) 4
Man(POEG3MTzAcNPh-CH2-S-Gal) 4
Man(PSEG3MTzAcNPh-O-Gal) 4
Man(PSEG3MTzAcNPh-CH2-S-Gal) 4
Man(PSEG2MTzAcNPh-CH2-S-Gal) 4
Man(PSEG3MTzAcNPh-S-Gal) 4
Man(PSEG2MTzAcNPh-O-Gal) 4
Man(PSEG2MTzAcNPh-SGal) 4
Man(POG2MTzAcNPh-SGal) 4
Man(POEG3MTzAcNPh-SGal) 4
Man(POEG3MTzproNCONapht-OGal) 4
Man(POEG3MTzproNCOBisph-OGal) 4
Man(PSEG3MTzproNCOBisph-OGal) 4
Man(PSEG2MTzproNCOBisph-OGal) 4
Man(POEG2MTz AcNPh-O-Gal) 4
Man(PSEG3MTzproNCONapht-O-Gal) 4
Man(POEG3MTz AcNPh-O-Gal) 4
Man(PSEG2MTzproNCONapht-O-Gal) 4
Man(POEG2MTzproNCOBisph-O-Gal) 4
Man(POEG2MTzproNCONapht-O-Gal) 4
wherein Man represents mannose, Gal represents galactose, Glc represents glucose.
17. The molecule according to claim 3 , wherein Ar is a phenyl group.
18. The molecule according to claim 3 , wherein z is 3 or 4.
19. The molecule according to claim 4 , wherein z is 3 or 4.